Thalidomide for the treatment of angiodysplasia‐related recurrent gastrointestinal hemorrhage: Is low dose a safe and viable option?

Thalidomide is often used for the management of refractory gastrointestinal angiodysplasia (GIAD). The tolerance, toxic profile, and compliance of thalidomide are dose‐dependent. The low‐dose thalidomide (50 mg) is safe and a viable option for bleeding related to GIAD.

Detalles Bibliográficos
Autores principales: Patel, Harish, Mehershahi, Shehriyar, Shaikh, Danial Haris, Makker, Jasbir, Nayudu, Sureshkumar, Remy, Prospere, Chilimuri, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935600/
https://www.ncbi.nlm.nih.gov/pubmed/31893059
http://dx.doi.org/10.1002/ccr3.2501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935600/
https://www.ncbi.nlm.nih.gov/pubmed/31893059
http://dx.doi.org/10.1002/ccr3.2501

Ejemplares similares